建立用于检测前列腺癌复发灶的68Ga-PSMA PET/CT标准化图像判读方法
本研究由欧洲核医学协会(EANM)推动和资助,旨在为根治性治疗后生化复发的前列腺癌患者定义68Ga-PSMA PET/CT标准化图像判读标准。第一阶段7个国际中心7名判读者对49例患者图像进行判读,任何部位异常发现的判读者间一致性仅为中等(Krippendorff's alpha=0.47),判断异常发现为病理性、不确定或非病理性时一致性提高至实质性(alpha=0.64)。经两轮Delphi后仅剩4例分歧,最终达成共识判读标准表。
要点
- 7名判读者对49例生化复发患者68Ga-PSMA PET/CT任何部位异常发现的判读一致性仅为中等(K's alpha=0.47)。
- 判断异常发现为病理性、不确定或非病理性时判读者间一致性提高至实质性(K's alpha=0.64)。
- 经两轮Delphi讨论后仅剩4例分歧,最终形成共识判读标准表。
核心结论
- 作者希望这些关于68Ga-PSMA PET/CT判读的共识指南能使临床医生提供更一致的临床报告,并在临床试验中统一异常分类,从而更稳健地评估其诊断性能。
研究设计与样本
- 本研究由欧洲核医学协会(EANM)推动和资助,旨在为根治性治疗后生化复发的前列腺癌患者定义68Ga-PSMA PET/CT标准化图像判读标准。
- 第一阶段由来自7个国际中心的7名判读者对49例生化复发患者的68Ga-PSMA PET/CT图像进行判读,计算判读者间一致性。
- 每名判读者评估5个不同复发部位(局部、局部区域淋巴结、远处淋巴结、骨和其他)的发现。
- 第二阶段仅重新分析一致性差、轻微、中等或一般(Krippendorff's alpha<0.61)的病例。
- 最终基于共识判读,制定修订的68Ga-PSMA PET/CT判读共识标准列表。
主要发现
- 判读者间对5个部位中任何部位存在异常发现的一致性仅为中等(K's alpha=0.47)。
- 当判读者需判断异常发现为病理性、不确定或非病理性图像时,一致性提高并达到实质性(K's alpha=0.64)。
- 还计算并评估了5个复发部位各自的K's alpha值。
- 进行了第一轮Delphi,项目协调员提出更详细的标准定义,经7名判读者讨论并最终同意。
- 第二轮Delphi后仅剩4例分歧,经最终轮评估后形成最终一致表。
关键数值与推荐
- 判读者间对任何部位异常发现存在与否的一致性为中等(K's alpha=0.47)。
- 判读者间对异常发现判断为病理性、不确定或非病理性的一致性为实质性(K's alpha=0.64)。
- 第二阶段重新分析限于Krippendorff's alpha<0.61的病例。
- 第二轮Delphi后仅剩4例分歧,最终轮后达成最终一致表。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
METHODS: After primary treatment, biochemical relapse (BCR) occurs in a substantial number of patients with prostate cancer (PCa). PET/CT imaging with prostate-specific membrane antigen based tracers (68Ga-PSMA) has shown promising results for BCR patients. However, a standardized image interpretation methodology has yet to be properly agreed. The aim of this study, which was promoted and funded by European Association of Nuclear Medicine (EANM), is to define standardized image interpretation criteria for 68Ga-PSMA PET/CT to detect recurrent PCa lesions in patients treated with primary curative intent therapy (radical prostatectomy or radiotherapy) who presented a biochemical recurrence. In the first phase inter-rater agreement between seven readers from seven international centers was calculated on the reading of 68Ga-PSMA PET/CT images of 49 patients with BCR. Each reader evaluated findings in five different sites of recurrence (local, loco-regional lymph nodes, distant lymph nodes, bone, and other). In the second phase the re-analysis was limited to cases with poor, slight, fair, or moderate agreement [Krippendorff's (K) alpha<0.61]. Finally, on the basis of the consensus readings, we sought to define a list of revised consensus criteria for 68Ga-PSMA PET/CT interpretation. RESULTS: Between-reader agreement for the presence of anomalous findings in any of the five sites was only moderate (K's alpha: 0.47). The agreement improved and became substantial when readers had to judge whether the anomalous findings were suggestive for a pathologic, uncertain, or non-pathologic image (K's alpha: 0.64). K's alpha calculations for each of the five sites of recurrence were also performed and evaluated. First Delphi round was thus conducted. A more detailed definition of the criteria was proposed by the project coordinator, which was then discussed and finally agreed by the seven readers. After the second Delphi round only four cases of disagreement still remained. These were evaluated for a final round, allowing a final agreement table to be written. CONCLUSION: We hope that by developing these consensus guidelines on the interpretation of 68Ga-PSMA PET/CT, clinicians reporting these studies will be able to provide more consistent clinical reports and that within clinical trials, abnormality classifications will be harmonized, allowing more robust assessment of its diagnostic performance.
引用
- Fanti S, Minozzi S, Morigi JJ, et al. Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. Eur J Nucl Med Mol Imaging. 2017. PMID: 28536833. doi:10.1007/s00259-017-3725-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。